1 / 51

Gout: It didn't need to come to this!

Gout: It didn't need to come to this!. Presenter: . Speaker Disclosure Statement. Name of presenter/speaker Gout : It didn't need to come to this! Financial Disclosure: Grants/Research Support Speaker Bureau/Honoraria Consulting Fees Other . %.

dyllis
Download Presentation

Gout: It didn't need to come to this!

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Gout: It didn't need to come to this! Presenter:

  2. Speaker Disclosure Statement Name of presenter/speaker Gout: It didn't need to come to this! Financial Disclosure: • Grants/Research Support • Speaker Bureau/Honoraria • Consulting Fees • Other

  3. % • 86% (71/81) of patients who had serum urate <360 µmol/L did not experience an acute flare during the study period

  4. Reduction in Acute Flaresin Years 2 and 3 of Treatment1 100 N = 267 80 Percentage of Patients With Gout Flare Recurrence 60 40 20 0 300 480 510 Mean Serum Urate, µmol/L

  5. .

  6. .

  7. Febuxostat 40 mg 50 Febuxostat 80 mg Allopurinol 300/200 mg 40 30 Subjects, % 20 10 0 0-4 4-8 8-12 12-16 16-20 20-24 24-28

More Related